I'm sorry
Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market capitalization in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end its collaboration with the company for its gene therapy gyroctocogen fitelparvovec targeting bleeding hemophilia A disorder.
Sangamo's (